In Plain English:
SNAP-8 is a lab-made peptide that copies part of a protein your nerve terminals need to fire. When you apply it to skin, it slots into the molecular machinery that triggers muscle contraction — not locking it down completely like Botox, but turning the volume down. The result in a 28-day manufacturer-sponsored trial was up to 63% fewer wrinkles around the eyes, with milder effect than a neuromodulator injection but no downtime, no needles, and no nerve damage. It was developed by Lipotec S.A. (now Lubrizol Life Science) in Barcelona as a longer, more potent extension of Argireline.
Research Maturity
Limited Human (102 PubMed results for SNAP-8 / acetyl octapeptide; most efficacy data manufacturer-commissioned+ Studies)
Focus
Cosmetic Dermatology
Skin Aging
Wrinkle Appearance
Origin
Synthesized by Lipotec S.A., Barcelona, Spain (now Lubrizol Life Science). First described in proprietary dossiers supporting the SNAP-8™ trade name. INCI-registered as Acetyl Glutamyl Heptapeptide-1; PubChem CID 71587832. The sequence extends Argireline (6AA) by adding C-terminal Ala-Asp, improving SNAP-25 binding coverage.
Mechanism
Mimics the N-terminal domain of SNAP-25 (synaptosome-associated protein 25 kDa). Competes with endogenous SNAP-25 for incorporation into the ternary SNARE complex (SNAP-25 / syntaxin / VAMP). Occupying the SNAP-25 binding site destabilises complex formation, reducing synaptic vesicle fusion efficiency and attenuating acetylcholine release at the neuromuscular junction. Effect is reversible competitive inhibition — no enzymatic cleavage of SNAP-25 (contrast botulinum toxin). Manufacturer data also report inhibition of catecholamine exocytosis and secondary stimulation of endogenous collagen synthesis at the level of fibroblast ECM activity.
Outcome
Manufacturer-sponsored split-face in vivo study (17 female volunteers, 28 days, twice-daily 10% cream): maximum periorbital wrinkle depth reduction 63.13%, mean reduction 34.98% vs. −27.05% for 10% Argireline and −2.99% for placebo (silicon imprint topography). A separate formulation assessment showed 38% wrinkle depth reduction with a cream at 3% of a 0.05% SNAP-8 solution. 2024 RCT (Annals of Dermatology, PMID 39082657, n=24): dissolving microneedle patch containing acetyl octapeptide-3 significantly improved periorbital wrinkles, skin elasticity, and TEWL vs. placebo with no adverse events over 28 days. Inhibition of catecholamine release in vitro: up to 63% at 1.5 mM (Lipotec 2020 data); synergy with Leuphasyl: 47% combined vs. 43% SNAP-8 alone at 0.75 mM. Approximately 30% greater activity than Argireline at equivalent concentrations across in vitro and in vivo models.
